LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 550

Search options

  1. Book ; Online: Towards Gender Equality in Law

    Guney, Gizem / Davies, David / Lee, Po-Han

    An Analysis of State Failures from a Global Perspective

    2022  

    Author's details edited by Gizem Guney, David Davies, Po-Han Lee
    Keywords Sex ; Human rights ; Social policy ; Political planning
    Subject code 305.3
    Language English
    Size 1 Online-Ressource (XIX, 250 p)
    Edition 1st ed. 2022
    Publisher Springer International Publishing ; Imprint: Palgrave Macmillan
    Publishing place Cham
    Document type Book ; Online
    HBZ-ID HT021412844
    ISBN 978-3-030-98072-6 ; 9783030980719 ; 9783030980733 ; 9783030980740 ; 3-030-98072-3 ; 3030980715 ; 3030980731 ; 303098074X
    DOI 10.1007/978-3-030-98072-6
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  2. Book ; Online: Towards Gender Equality in Law

    Guney, Gizem / Davies, David / Lee, Po-Han

    An Analysis of State Failures from a Global Perspective

    2022  

    Keywords Gender studies, gender groups ; Human rights ; Central government policies ; Social work ; Transgender ; Gender-based violence ; Socio-legal ; Reproductive rights ; Sex work ; Hate speech
    Language 0|e
    Size 1 electronic resource (250 pages)
    Publisher Springer Nature
    Publishing place Cham
    Document type Book ; Online
    Note English ; Open Access
    HBZ-ID HT021610492
    ISBN 9783030980726 ; 3030980723
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  3. Article: CAR Based Immunotherapy of Solid Tumours-A Clinically Based Review of Target Antigens.

    Maher, John / Davies, David M

    Biology

    2023  Volume 12, Issue 2

    Abstract: Immunotherapy with CAR-engineered immune cells has transformed the management of selected haematological cancers. However, solid tumours have proven much more difficult to control using this emerging therapeutic modality. In this review, we survey the ... ...

    Abstract Immunotherapy with CAR-engineered immune cells has transformed the management of selected haematological cancers. However, solid tumours have proven much more difficult to control using this emerging therapeutic modality. In this review, we survey the clinical impact of solid tumour CAR-based immunotherapy, focusing on specific targets across a range of disease indications Among the many candidates which have been the subject of non-clinical CAR T-cell research, clinical data are available for studies involving 30 of these targets. Here, we map out this clinical experience, highlighting challenges such as immunogenicity and on-target off-tumour toxicity, an issue that has been both unexpected and devastating in some cases. We also summarise how regional delivery and repeated dosing have been used in an effort to enhance impact and safety. Finally, we consider how emerging armouring systems and multi-targeted CAR approaches might be used to enhance tumour access and better enable discrimination between healthy and transformed cell types.
    Language English
    Publishing date 2023-02-10
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2661517-4
    ISSN 2079-7737
    ISSN 2079-7737
    DOI 10.3390/biology12020287
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: CAR-Based Immunotherapy of Solid Tumours-A Survey of the Emerging Targets.

    Maher, John / Davies, David M

    Cancers

    2023  Volume 15, Issue 4

    Abstract: Immunotherapy with CAR T-cells has revolutionised the treatment of B-cell and plasma cell-derived cancers. However, solid tumours present a much greater challenge for treatment using CAR-engineered immune cells. In a partner review, we have surveyed data ...

    Abstract Immunotherapy with CAR T-cells has revolutionised the treatment of B-cell and plasma cell-derived cancers. However, solid tumours present a much greater challenge for treatment using CAR-engineered immune cells. In a partner review, we have surveyed data generated in clinical trials in which patients with solid tumours that expressed any of 30 discrete targets were treated with CAR-based immunotherapy. That exercise confirms that efficacy of this approach falls well behind that seen in haematological malignancies, while significant toxic events have also been reported. Here, we consider approximately 60 additional candidates for which such clinical data are not available yet, but where pre-clinical data have provided support for their advancement to clinical evaluation as CAR target antigens.
    Language English
    Publishing date 2023-02-11
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15041171
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: CAR Based Immunotherapy of Solid Tumours—A Clinically Based Review of Target Antigens

    Maher, John / Davies, David M.

    Biology (Basel). 2023 Feb. 10, v. 12, no. 2

    2023  

    Abstract: Immunotherapy with CAR-engineered immune cells has transformed the management of selected haematological cancers. However, solid tumours have proven much more difficult to control using this emerging therapeutic modality. In this review, we survey the ... ...

    Abstract Immunotherapy with CAR-engineered immune cells has transformed the management of selected haematological cancers. However, solid tumours have proven much more difficult to control using this emerging therapeutic modality. In this review, we survey the clinical impact of solid tumour CAR-based immunotherapy, focusing on specific targets across a range of disease indications Among the many candidates which have been the subject of non-clinical CAR T-cell research, clinical data are available for studies involving 30 of these targets. Here, we map out this clinical experience, highlighting challenges such as immunogenicity and on-target off-tumour toxicity, an issue that has been both unexpected and devastating in some cases. We also summarise how regional delivery and repeated dosing have been used in an effort to enhance impact and safety. Finally, we consider how emerging armouring systems and multi-targeted CAR approaches might be used to enhance tumour access and better enable discrimination between healthy and transformed cell types.
    Keywords T-lymphocytes ; immunogenicity ; immunotherapy ; neoplasms ; toxicity
    Language English
    Dates of publication 2023-0210
    Publishing place Multidisciplinary Digital Publishing Institute
    Document type Article ; Online
    ZDB-ID 2661517-4
    ISSN 2079-7737
    ISSN 2079-7737
    DOI 10.3390/biology12020287
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  6. Article ; Online: Laboratory Grown Biofilms of Bacteria Associated with Human Atherosclerotic Carotid Arteries Release Collagenases and Gelatinases during Iron-Induced Dispersion.

    Zdimal, Amanda M / Davies, David G

    Microbiology spectrum

    2022  Volume 10, Issue 3, Page(s) e0100121

    Abstract: The association of bacteria with arterial plaque lesions in patients with atherosclerosis has been widely reported. However, the role these bacteria play in the progression of atherosclerosis is still unclear. Previous work in our lab has demonstrated ... ...

    Abstract The association of bacteria with arterial plaque lesions in patients with atherosclerosis has been widely reported. However, the role these bacteria play in the progression of atherosclerosis is still unclear. Previous work in our lab has demonstrated that bacteria exist in carotid artery plaques as biofilm deposits. Biofilms are communities of microorganisms enmeshed within a protective, self-produced extracellular matrix and have been shown to contribute to chronic infections in humans. Biofilm communities have the potential to impact surrounding tissues in an infection if they undergo a dispersion response, releasing bacteria into the surrounding environment by enzymatic degradation of the extracellular matrix. One concern relating to these enzymes is that they could cause collateral damage to host tissues. In this study, we present an
    MeSH term(s) Atherosclerosis/pathology ; Bacteria ; Biofilms ; Carotid Arteries/microbiology ; Carotid Arteries/pathology ; Collagenases ; Gelatinases ; Humans ; Iron ; Myocardial Infarction/pathology ; Stroke/pathology
    Chemical Substances Iron (E1UOL152H7) ; Collagenases (EC 3.4.24.-) ; Gelatinases (EC 3.4.24.-)
    Language English
    Publishing date 2022-05-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2807133-5
    ISSN 2165-0497 ; 2165-0497
    ISSN (online) 2165-0497
    ISSN 2165-0497
    DOI 10.1128/spectrum.01001-21
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Cases and Dissections.

    Davies, David

    Medico-chirurgical journal : or, Quarterly register of medical and surgical science

    2017  Volume 1, Issue 4, Page(s) 472–476

    Language English
    Publishing date 2017-12-19
    Publishing country England
    Document type Journal Article
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Supplementary magnesium in traumatic brain injury: where do we go from here?

    Davies, David James

    Journal of the Royal Army Medical Corps

    2018  Volume 164, Issue 6, Page(s) 397–398

    MeSH term(s) Brain Injuries ; Brain Injuries, Traumatic ; Humans ; Magnesium
    Chemical Substances Magnesium (I38ZP9992A)
    Language English
    Publishing date 2018-06-18
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 840678-9
    ISSN 2052-0468 ; 0035-8665
    ISSN (online) 2052-0468
    ISSN 0035-8665
    DOI 10.1136/jramc-2018-000985
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Designing Inhibitors of β-Lactamase Enzymes to Overcome Carbapenem Resistance in Gram-Negative Bacteria.

    Davies, David T / Everett, Martin

    Accounts of chemical research

    2021  Volume 54, Issue 9, Page(s) 2055–2064

    Abstract: Ever since the first β-lactam antibiotic, penicillin, was introduced into the clinic over 70 years ago, resistance has been observed because of the presence of β-lactamase enzymes, which hydrolyze the β-lactam ring of β-lactam antibiotics. Early β- ... ...

    Abstract Ever since the first β-lactam antibiotic, penicillin, was introduced into the clinic over 70 years ago, resistance has been observed because of the presence of β-lactamase enzymes, which hydrolyze the β-lactam ring of β-lactam antibiotics. Early β-lactamase enzymes were all of the serine β-lactamase (SBL) type, but more recently, highly resistant Gram-negative strains have emerged in which metallo-β-lactamase (MBL) enzymes are responsible for resistance. The two types of β-lactamase enzymes are structurally and mechanistically different but serve the same purpose in bacteria. The SBLs use an active serine group as a nucleophile to attack the β-lactamase ring, forming a covalent intermediate that is subsequently hydrolyzed. In contrast, the MBLs use a zinc ion to activate the β-lactam toward nucleophilic attack by a hydroxide anion held between two zinc ions. In this Account, we review our recent contribution to the field of β-lactamase inhibitor design in terms of both SBL and MBL inhibitors. We describe how we have approached these challenges from the particular perspective of a small biotechnology company, identifying new inhibitors when faced with either a paucity of starting points for medicinal chemistry (MBL inhibitors) or else an abundance of prior research necessitating a search for novelty, improvement, and differentiation (SBL inhibitors). During the journey from the beginning of lead optimization to successful identification of a preclinical candidate for development, we encountered and solved a range of issues. For example, in the MBL inhibitor series we were able to prevent metabolic cleavage of a glycinamide moiety by circulating amidases while still retaining the activity by converting the amino group into a guanidine. In the SBL inhibitor series, the structure-activity relationship led us to consider introducing a fluorine substituent adjacent to a urea functionality. At first sight this grouping would appear to be chemically unstable. However, deeper theoretical considerations suggested that this would not be the case, and in practice the compound is remarkably stable. Both examples serve to illustrate the importance of scientific insight and the necessity to explore speculative hypotheses as part of the creative medicinal chemistry process.
    MeSH term(s) Anti-Bacterial Agents/chemical synthesis ; Anti-Bacterial Agents/chemistry ; Anti-Bacterial Agents/pharmacology ; Carbapenems/pharmacology ; Drug Design ; Drug Resistance, Bacterial/drug effects ; Gram-Negative Bacteria/drug effects ; Humans ; Microbial Sensitivity Tests ; beta-Lactamase Inhibitors/chemical synthesis ; beta-Lactamase Inhibitors/chemistry ; beta-Lactamase Inhibitors/pharmacology ; beta-Lactamases/metabolism
    Chemical Substances Anti-Bacterial Agents ; Carbapenems ; beta-Lactamase Inhibitors ; beta-Lactamases (EC 3.5.2.6)
    Language English
    Publishing date 2021-03-31
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1483291-4
    ISSN 1520-4898 ; 0001-4842
    ISSN (online) 1520-4898
    ISSN 0001-4842
    DOI 10.1021/acs.accounts.0c00863
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells.

    Davies, David M / Maher, John

    Cancer cell

    2021  Volume 39, Issue 2, Page(s) 138–140

    Abstract: CAR-engineered T cell immunotherapy has proven transformative in selected hematological malignancies. However, solid tumors largely remain impervious to these approaches. In addressing this challenge, Srivastava et al. in this issue demonstrate that ... ...

    Abstract CAR-engineered T cell immunotherapy has proven transformative in selected hematological malignancies. However, solid tumors largely remain impervious to these approaches. In addressing this challenge, Srivastava et al. in this issue demonstrate that oxaliplatin-based lymphodepleting chemotherapy promotes enhanced CAR T cell recruitment to lung tumors, boosting therapeutic impact in combination with anti-PD-L1.
    Language English
    Publishing date 2021-01-07
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 2078448-X
    ISSN 1878-3686 ; 1535-6108
    ISSN (online) 1878-3686
    ISSN 1535-6108
    DOI 10.1016/j.ccell.2020.12.019
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top